In this activity, Dr. Rami Komrokji explains which investigational studies to review in the post-AZA setting.

In this activity, Dr. Rami Komrokji discusses the recent progress made in anemia management and lower-risk MDS.

In this activity, Dr. Rami Komrokji describes the best way to determine treatment for patients with SF3B1 mutation.

The treatment of patients with RARS involves supportive care strategies and includes ESAs, transfusions, and iron chelation. In this activity, Dr. Navada outlines the appropriate treatment strategies.

In this activity, Dr. Shyamala Navada describes refractory anemia with ring sideroblasts and what this presence means for your patient with MDS.

Join Dr. David Sallman as he gives an exciting update regarding the potential pipeline in MDS.

In this activity, Dr. Padron discusses patients developing iron overload after receiving a red blood cell transfusion and the current standard of care to minimize the consequences of this occurrence.

In this activity, Dr. Padron discusses the positive activity of luspatercept in clinical trials with low-risk MDS and where this may be an appropriate option.

Dr. Park outlines the importance of assessment for IDH mutations in your patients with MDS, as the presence of these mutations significantly impacts prognosis.

Dr. Park summarizes the use of IDH1/2 inhibitors in the AML setting and how this treatment may apply to your patients with MDS.